13.98
전일 마감가:
$13.94
열려 있는:
$14
하루 거래량:
263.84K
Relative Volume:
0.15
시가총액:
$888.02M
수익:
$15.84M
순이익/손실:
$-308.48M
주가수익비율:
-2.1582
EPS:
-6.48
순현금흐름:
$-153.08M
1주 성능:
-1.48%
1개월 성능:
-3.18%
6개월 성능:
-20.67%
1년 성능:
+215.19%
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
QURE
Uniqure N V
|
13.99 | 888.02M | 15.84M | -308.48M | -153.08M | -6.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.32 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
536.13 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
323.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
552.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-01 | 재개 | Chardan Capital Markets | Buy |
2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
2021-06-15 | 개시 | BTIG Research | Buy |
2021-05-21 | 개시 | UBS | Neutral |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-11-24 | 개시 | H.C. Wainwright | Buy |
2020-11-11 | 개시 | Berenberg | Buy |
2020-11-09 | 개시 | Jefferies | Buy |
2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
2020-08-25 | 개시 | Raymond James | Strong Buy |
2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | 개시 | Cowen | Outperform |
2019-12-03 | 개시 | Goldman | Buy |
2019-11-05 | 개시 | Credit Suisse | Outperform |
2019-10-11 | 개시 | Stifel | Buy |
2019-09-25 | 개시 | Bernstein | Outperform |
2019-09-12 | 개시 | Mizuho | Buy |
2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
2019-04-12 | 개시 | Piper Jaffray | Overweight |
2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure shareholders approve executive compensation, board reappointments - Investing.com
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease wi - GuruFocus
uniQure aligns with FDA on Huntington’s therapy path - Investing.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus
uniQure Advances AMT-130 for Huntington's Disease with FDA Alignment, BLA Submission Planned for Q1 2026 - Nasdaq
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire
FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment - Stock Titan
uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital - Defense World
HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright - Defense World
QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus
uniQure presents case study of first patient dosed with AMT-260 - TipRanks
uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus
uniQure early AMT-260 data encouraging, says H.C. Wainwright - TipRanks
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE Stock News - GuruFocus
uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus
Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan
Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail
Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com
uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha
Northern Trust Corp Buys 1,923 Shares of uniQure (NASDAQ:QURE) - Defense World
Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World
uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure N V 주식 (QURE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
자본화:
|
볼륨(24시간):